AstraZeneca, Takeda gout acquisitions make BCRX hopeful for gout drug deal

The gout drug candidate BioCryst (NASDAQ:BCRX) is developing now has the green light to advance into phase 3 clinical trials, but some of the best news CEO Jon Stonehouse heard recently came from busi…
Read the full story: MedCity News